Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019

Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study

(2022) Daniel J Sheward et al.   LANCET INFECTIOUS DISEASES

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

(2022) Myron J. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19: Has the spread of omicron BA.2 made antibody treatments redundant?

(2022) Elisabeth Mahase   BMJ-British Medical Journal

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

(2022) Hugh Montgomery et al.   Lancet Respiratory Medicine

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns

(2021) Anthony Touafchia et al.   CLINICAL MICROBIOLOGY AND INFECTION

Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)

(2020) François Montastruc et al.   Clinical Gastroenterology and Hepatology

VigiBase, the WHO Global ICSR Database System: Basic Facts

(2017) Marie Lindquist   DRUG INFORMATION JOURNAL